Our goal as a company is to eliminate the inevitability of amputations due to diabetic foot ulcers
Irvine, CA (PRWEB) August 05, 2016
Modulated Imaging announced today that they have been awarded a $1.8 million SBIR Phase II grant by the National Institutes of Health to further develop their Ox-Imager CS (pending FDA clearance) technology to help predict and manage the treatment of diabetic foot ulcers. This grant will support three clinical studies, as well as the research and development of a point-of-care diagnostic system.
Diabetic foot ulcers are the most common cause of lower limb amputations, because once they form, they are notoriously difficult to treat. It is estimated that the cost of treating diabetic foot ulcers is as high as $13 billion per year to the US healthcare system alone. In addition to the economic costs, patients have a much lower quality of life, and have a shorter life expectancy once they have developed a diabetic foot ulcer. Currently, there are no simple to use and accurate technologies to identify diabetic patients who are at-risk for forming a foot ulcer.
“Our Ox-Imager device is a non-contact optical imaging system which provides physicians with real-time information on tissue health,” stated Amaan Mazhar, PhD, Modulated Imaging’s Vice President of R&D and the grant’s principal investigator. “This grant from the NIH will allow us to further refine the Ox-Imager through clinical studies and technology development. Our goal as a company is to eliminate the inevitability of amputations due to diabetic foot ulcers.”
In addition to this grant, in July 2016 Modulated Imaging closed its first round of venture capital financing, with investment from The Cove Fund and Photonics Management Corp, a subsidiary of Hamamatsu Photonics KK.
About Modulated Imaging
Modulated Imaging is a leading developer of light-based imaging systems for both scientific and medical application. The company was spun-out from the Photonic Incubator at the University of California Irvine’s Beckman Laser Institute, and uses ground breaking light-based technology to impact the future of skin health. Their patented SFDI tissue-imaging devices gives medical, research and aesthetics professionals cutting-edge ways to prevent, diagnose and cure underlying skin conditions.
The research discussed in this press release is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R44DK094625. The content of the press release is solely the responsibility of Modulated Imaging, Inc. and does not necessarily represent the official views of the National Institutes of Health.
For more information, contact Julene Cray, RN, Vice President of Business Development at julene.cray(at)modulatedimaging(dot)com.